Long-term treatment with raltegravir or efavirenz combined with tenofovir/emtricitabine for treatment-naive human immunodeficiency virus-1-infected patients: 156-week results from STARTMRK.
about
Efficacy, safety, and patient acceptability of elvitegravir/cobicistat/emtricitabine/tenofovir in the treatment of HIV/AIDSClinical use of HIV integrase inhibitors: a systematic review and meta-analysisAtherosclerotic Cardiovascular Disease and Anti-Retroviral Therapy.HIV integrase inhibitors: a new era in the treatment of HIV.Critical appraisal of elvitegravir in the treatment of HIV-1/AIDS.The emerging profile of cross-resistance among the nonnucleoside HIV-1 reverse transcriptase inhibitors.Rapid screening of HIV reverse transcriptase and integrase inhibitors.Current perspectives in HIV post-exposure prophylaxis.The potential cost and benefits of raltegravir in simplified second-line therapy among HIV infected patients in Nigeria and South AfricaHIV-associated lipodystrophy: impact of antiretroviral therapy.Dolutegravir, the Second-Generation of Integrase Strand Transfer Inhibitors (INSTIs) for the Treatment of HIV.Polymorphisms of Pyrimidine Pathway Enzymes Encoding Genes and HLA-B*40∶01 Carriage in Stavudine-Associated Lipodystrophy in HIV-Infected Patients.Comparative changes of lipid levels in treatment-naive, HIV-1-infected adults treated with dolutegravir vs. efavirenz, raltegravir, and ritonavir-boosted darunavir-based regimens over 48 weeks.Effects of switching from stavudine to raltegravir on subcutaneous adipose tissue in HIV-infected patients with HIV/HAART-associated lipodystrophy syndrome (HALS). A clinical and molecular studyEpidemiology and management of antiretroviral-associated cardiovascular disease.Raltegravir in HIV-1 infection: Safety and Efficacy in Treatment-naïve Patients.Cocaine promotes both initiation and elongation phase of HIV-1 transcription by activating NF-κB and MSK1 and inducing selective epigenetic modifications at HIV-1 LTRSafety, tolerability, and efficacy of raltegravir in a diverse cohort of HIV-infected patients: 48-week results from the REALMRK Study.Pharmacokinetics and pharmacodynamics of once-daily versus twice-daily raltegravir in treatment-naive HIV-infected patientsA prospective, randomized clinical trial of antiretroviral therapies on carotid wall thickness.Initiation of antiretroviral therapy at high CD4+ cell counts is associated with positive treatment outcomes.Patient-reported symptoms on the antiretroviral regimen efavirenz/emtricitabine/tenofovirSafety, Pharmacokinetics and Efficacy of Dolutegravir in Treatment-experienced HIV-1 Infected Adolescents: Forty-eight-week Results from IMPAACT P1093A novel ultrasensitive LC-MS/MS assay for quantification of intracellular raltegravir in human cell extracts.The metabolic and cardiovascular consequences of obesity in persons with HIV on long-term antiretroviral therapyAbacavir/lamivudine versus tenofovir/emtricitabine in virologically suppressed patients switching from ritonavir-boosted protease inhibitors to raltegravir.ART influences HIV persistence in the female reproductive tract and cervicovaginal secretions.Outcomes of second combination antiretroviral therapy regimens among HIV-infected persons in clinical care: a multicenter cohort study.Body Composition Changes After Initiation of Raltegravir or Protease Inhibitors: ACTG A5260sSuperior Glucose Tolerance and Metabolomic Profiles, Independent of Adiposity, in HIV-Infected Women Compared With Men on Antiretroviral TherapyAssociation between daily antiretroviral pill burden and treatment adherence, hospitalisation risk, and other healthcare utilisation and costs in a US medicaid population with HIVCost-effectiveness of the once-daily efavirenz/emtricitabine/tenofovir tablet compared with the once-daily elvitegravir/cobicistat/emtricitabine/tenofovir tablet as first-line antiretroviral therapy in HIV-infected adults in the USEconomic evaluation of initial antiretroviral therapy for HIV-infected patients: an update of Italian guidelines.Dyslipidemia and cardiovascular risk in human immunodeficiency virus infection.Pharmacokinetics, safety, and 48-week efficacy of oral raltegravir in HIV-1-infected children aged 2 through 18 years.Resistance to HIV integrase strand transfer inhibitors among clinical specimens in the United States, 2009-2012.Increases in duration of first highly active antiretroviral therapy over time (1996-2009) and associated factors in the Multicenter AIDS Cohort Study.Single tablet regimens are associated with reduced Efavirenz withdrawal in antiretroviral therapy naïve or switching for simplification HIV-infected patients.Efficacy and safety of maraviroc vs. efavirenz in treatment-naive patients with HIV-1: 5-year findingsThe adolescent and young adult HIV cascade of care in the United States: exaggerated health disparities.
P2860
Q26783253-8ED21A4E-98CD-42DC-96F2-7346F1C37FA5Q28484930-EBC09032-2FCE-48C2-82BC-11C102B1C5F7Q30248286-B4E4E34A-F0DB-48CE-9692-108ED4A1E93DQ30956943-1A69E6C0-F797-45D4-88AC-AD73A9B0296CQ33680234-BAE6DA5C-E11E-4ED1-8312-FC4CBC54EC27Q34102246-71076ECC-6B65-4A66-A988-B2E53EEDC6EDQ34193340-83C29549-7D2E-419E-93CD-E01F8D706AD4Q34434815-33C0373E-8C68-4C9D-9DDA-8A41989157C3Q34606231-FF508DC7-39B1-4857-B44E-6926A25620BFQ34655845-5F0055CB-D9BD-44C6-91CC-18D5E6D60369Q34726183-9DCEBB13-135D-4EC1-B42D-E1AF727F5813Q34806335-9EDFF8A7-4640-41F3-9448-CDBB1020B26CQ35103606-81F91818-35D3-4A6D-A114-6BA49EC60E0EQ35106654-BEE4D0FE-4910-44D6-B9B3-3755671590D7Q35338096-209B5901-7EB0-4C65-9788-305C4032C636Q35789343-9822F207-C7E0-4481-9153-EE4ADC727E5BQ35894061-75B9073C-03E3-4197-B115-8572FBC28B70Q35896106-455AD047-8017-4F66-B492-F713F4D28FB3Q36018635-96940D0F-0281-4E12-9D5F-C371160DCBAFQ36063551-453D3B3C-53C4-431D-9AC3-FF7DFA97B07EQ36070585-526673CB-28AC-42A1-9411-7ADB43A9FEF5Q36142875-6BF5F76E-168B-4344-BDD2-F63296709934Q36157266-296DAD9F-AE7D-410B-AF0E-E98E5173ABADQ36236691-1D402DD3-136D-4BC5-821D-13C55587ABE0Q36436780-A54A3A36-131B-47F7-AC6A-7B2ECAA33392Q36553976-A1135AA9-A808-46F3-B526-58339C2716F8Q36618563-2F35A5B2-DFB1-4602-AC8B-D85D59396E28Q36634843-D4D2A388-81B5-4849-9B11-32BF4EC90D30Q36676379-CED4C836-13A7-444A-A9D5-0F79120F5765Q36993493-F333A526-C1D5-4DEE-8CAD-91852AAD5B69Q37069682-D5ABACF7-E7B0-4049-9BC5-8F969B3B5A29Q37164594-34DEFF08-B848-4F32-B7F5-B4BE240BA017Q37225380-57917C0D-6EB6-4CBD-90A1-B9CA69004337Q37319195-AE03C97A-4E61-4DE5-8530-290CA7508F05Q37473017-1C71A37A-7769-4978-B07A-5E06D69E451FQ37473023-766D4323-092D-491C-A71F-2E5518769D91Q37497586-C6F19920-1EEB-46EB-841A-E0F187776623Q37501229-E61BB0B6-7EBB-4815-A1FF-57C7B89EB2C7Q37613476-BE7A25FD-6D7F-462F-90DF-D01EFB103CE8Q37628307-CFE77317-6D14-4F3A-91CE-8AE27C904658
P2860
Long-term treatment with raltegravir or efavirenz combined with tenofovir/emtricitabine for treatment-naive human immunodeficiency virus-1-infected patients: 156-week results from STARTMRK.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年学术文章
@wuu
2011年学术文章
@zh
2011年学术文章
@zh-cn
2011年学术文章
@zh-hans
2011年学术文章
@zh-my
2011年学术文章
@zh-sg
2011年學術文章
@yue
2011年學術文章
@zh-hant
name
Long-term treatment with ralte ...... 56-week results from STARTMRK.
@en
Long-term treatment with ralte ...... 56-week results from STARTMRK.
@nl
type
label
Long-term treatment with ralte ...... 56-week results from STARTMRK.
@en
Long-term treatment with ralte ...... 56-week results from STARTMRK.
@nl
prefLabel
Long-term treatment with ralte ...... 56-week results from STARTMRK.
@en
Long-term treatment with ralte ...... 56-week results from STARTMRK.
@nl
P2093
P2860
P356
P1476
Long-term treatment with ralte ...... 56-week results from STARTMRK.
@en
P2093
Anthony J Rodgers
Bach-Yen Nguyen
Edwin Dejesus
Hedy Teppler
Jeffrey L Lennox
Mark J Dinubile
Michael S Saag
Monica L Walker
P2860
P304
P356
10.1093/CID/CIR510
P407
P577
2011-10-01T00:00:00Z